Related Experiment Video
Updated: Jun 7, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Starting points for the development of new targeted therapies for glioblastoma multiforme
Agnieszka Rusak1, Benita Wiatrak2, Klaudia Krawczyńska1
1Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, T. Chalubinskiego 6a St., Wroclaw 50-368, Poland.
Abstract:
Glioblastoma multiforme (GBM) is one of the most aggressive and lethal brain tumors, characterized by rapid growth, invasiveness, and resistance to standard therapies, including surgery, chemotherapy, and radiotherapy. Despite advances in treatment, GBM remains highly resistant due to its complex molecular mechanisms, including angiogenesis, invasion, immune modulation, and lipid metabolism dysregulation. This review explores recent breakthroughs in targeted therapies, focusing on innovative drug carriers such as nanoparticles and liposomes, and their potential to overcome GBM's chemo- and radioresistant phenotypes. We also discuss the molecular pathways involved in GBM progression and the latest therapeutic strategies, including immunotherapy and precision medicine approaches, which hold promise for improving clinical outcomes. The review highlights the importance of understanding GBM's genetic and molecular heterogeneity to develop more effective, personalized treatment protocols aimed at increasing survival rates and enhancing the quality of life for GBM patients.
Insights
Glioblastoma multiforme (GBM) is a deadly brain cancer resistant to treatment. New targeted therapies using nanoparticles and liposomes show promise for overcoming resistance and improving patient survival.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Pharmacology
Background:
- Glioblastoma multiforme (GBM) is a highly aggressive and lethal primary brain tumor.
- GBM exhibits significant resistance to conventional treatments like surgery, chemotherapy, and radiotherapy.
- Tumor resistance is driven by complex molecular mechanisms including angiogenesis, invasion, immune modulation, and altered lipid metabolism.
Purpose of the Study:
- To review recent advancements in targeted therapies for glioblastoma multiforme.
- To explore the potential of innovative drug delivery systems, such as nanoparticles and liposomes, in overcoming treatment resistance.
- To discuss molecular pathways and emerging therapeutic strategies like immunotherapy and precision medicine for improved clinical outcomes.
Main Methods:
- Literature review of recent breakthroughs in glioblastoma multiforme targeted therapies.
- Analysis of molecular mechanisms underlying GBM progression and therapeutic resistance.
- Evaluation of novel drug delivery systems (nanoparticles, liposomes) and treatment modalities (immunotherapy, precision medicine).
Main Results:
- Targeted therapies utilizing nanoparticles and liposomes demonstrate potential in overcoming chemo- and radioresistant phenotypes of GBM.
- Understanding molecular pathways and genetic heterogeneity is crucial for developing effective treatment strategies.
- Immunotherapy and precision medicine approaches offer promising avenues for improving patient survival and quality of life.
Conclusions:
- Innovative drug carriers and advanced therapeutic strategies are essential for tackling glioblastoma multiforme resistance.
- Personalized treatment protocols based on GBM's molecular heterogeneity are key to enhancing patient outcomes.
- Further research into targeted therapies, immunotherapy, and precision medicine holds significant promise for improving glioblastoma survival rates.
